not scale like a biotech company.
Diagnostics are simply not as valuable..
While the perma longs here have little concern about this value destruction, many longs see this decline as confirmation of the very long term problems Ariad must deal with. It is the dismal view of this company's situation that has made the takedown so easy. Apart from the molecule next announcement, we have a dearth of positive news for nearly 24 months. Of course, we still may have some bad news.
Nobody on Wall Street is buying HB's promises or sweet talk anymore. Folks thinking he is going to pull a rabbit out of his hat, that idea is delusional, even I have abandoned it. No Rabbit. No hat. Go back and read your posts from 5 years ago. You could cut and paste that same nonsense instead of rewriting it now.
The decline, and my conversation with IR, has confirmed that pessimistic view far more than my positive view. We know:
-Iclusig will be a dog for 2 years minimum. There is nothing that is going to change that. Not Cortes, not dosing, not GIST, not IST's, nothing. Minimum 2 years for anything. Ditto '113.
-The stock is still fully exposed to every market contagion at beta, and then some, like the Fed. We could go much lower, and probably will.
-Q2 will confirm the double whammy of 15mg pricing, and 25%+ drops, due to the sickest of patients taking Iclusig.
-PRAC will not be a positive development (but not the worst)
-Molecule next is basically a Hail Mary by Ariad. If it is announced (even Jess sees a possible 15 month delay), it is hoped just the announcement is a value add. We have to borrow more money to even get the drug into the clinic. We can barely afford to sell Iclusig. After Rida, and Pona woes, this difficult target will not have the best of odds.
We need to look no further than the incompetence of the Board of Directors. From $25 to $2 to the 9's to $5.37, all in a year, it is all so unacceptable.
This isn't a company of unknown substance like we were 6 years ago, rattling around in the $2’s or lower. This is a company of substance bei
So it seems
I just don't know..
enough for me..
What stupidity.. On the call, they were all flash and no substance. Both of them
Not making enough money, poor guidance, poor prospects, two application fails. Results from the oral mucositis trial not enough color to make me want to hold this. I needed to hear at least some subjective description of effectiveness. If it's too hard to say, then it didn't work.. So the company likes to trade its own stock...buy at $4, sell @ $10....maybe I'll do the same. good luck.
Zelnorm was withdrawn from the U.S. market on March 30, 2007. This medication may still be used in limited emergency situations.
Huge risk for heart attacks..
You've got to be kidding!
The companies are also evaluating potential impact to the timing of initiation of the second pivotal trial in the global, multicenter Phase 3 program for pediatric functional constipation in children aged 6 months to less than 6 years, as the liquid formulation would be required for this study.
Reply to Bought more today at $7.77 by sophia.leghorn •22 hours ago
shirazi2001us • 20 hours ago
0users liked this postsusers disliked this posts0Reply
I added 5k at average price of $7.80.
This was SCMP partner who did not know how to apply for approval and put 3 different phase 3 in application and unfortunately MHRA chose only one, the one that was not related to OIC
Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP) is developing Amitiza in collaboration with its partner Takeda Pharmaceuticals, which markets the drug in the United Stats. Amitiza sales from the U.S. came in at $78.0 million, up 4.6% year over year. Total prescriptions for Amitiza increased 5% in 2013 and 6% in the fourth quarter in the U.S. The drug already has FDA approval for three conditions, and the company has recently filed for a fourth. The Cantor Fitzgerald price target is $12, and the consensus target is $10.25 (edit: now over $11 on Yahoo). Sucampo was trading at $8.30 on Friday. A move to the target would be a 45% gain.
Read more: Low-Priced Biotech Stocks That Could Double (or More) - 24/7 Wall St. http://247wallst.com/healthcare-business/2014/03/08/low-priced-biotech-stocks-that-could-double/#ixzz2veumJG2i
Follow us: @247wallst on Twitter | 247wallst on Facebook
This is a great investment.Upgrades for sure.